ASO for Melanoma
Melanoma
Pre-clinicalActive
Key Facts
About Carnation Therapeutics
Carnation Therapeutics is an early-stage biotech leveraging antisense oligonucleotide technology to target cancer at the genetic level. Founded in 2022, the company is in the preclinical research phase, developing therapies for high-need oncology indications such as lung cancer and melanoma. Operating as a private, pre-revenue entity, it aims to grow into a leading innovator by modulating protein expression through mRNA interaction, offering a novel approach to difficult-to-treat cancers.
View full company profileTherapeutic Areas
Other Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ABD-3001 | Advanced Biodesign | Phase 1 |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| Cannabics® MLN-33 | CNBX Pharmaceuticals | Discovery |
| AV-MEL-1 | AIVITA Biomedical | Phase 1B |
| Melanoma Immunotherapy | Vaccizone | Pre-clinical |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Melanoma Monitoring Solution | Oncobit | Commercial |
| Undisclosed Enhanced Antibody Program | Score Pharma | Pre-clinical |
| Personalized DNA Cancer Vaccine | Neomatrix | Pre-clinical |